GB-115 & CCK analoguesГБ-115
A synthetic dipeptide derivative containing L-tryptophan, designed from cholecystokinin tetrapeptide (CCK-4). Human anxiety trials studied the oral formulation Ranquilon.
What the studies found
Randomized study in people · 2024
220-person placebo trial: 70% versus 24.5% anxiety response
- Primary ≥50% HARS response
- 77/110 (70.0%) versus 27/110 (24.5%)Day 29 ± 1p<0.0001
- Response-rate difference
- 45.5 percentage pointsAbsolute difference, not a 45.5% relative reduction
- HARS decrease · day 29
- 11.90 ± 4.88 versus 5.43 ± 5.03 pointsp<0.0001
At day 29, 77/110 (70.0%) Ranquilon recipients achieved at least a 50% HARS anxiety-score reduction versus 27/110 (24.5%) on placebo (p<0.0001). The reported response-rate difference was 45.5 percentage points.
More reported outcomes
- Patients with adverse events
- 28/110 (25.5%) versus 16/110 (14.6%)p=0.063
- Adverse-event counts
- 43 active-arm events; 21 placebo-arm eventsNo serious events or adverse-event discontinuations reported
Study notes · methods, sources and limitations
Participants or model 220 adults, 110 Ranquilon and 110 placebo; 28 days of treatment.
Important limitations
- Neurasthenia and adjustment disorders; do not relabel this as a generalized-anxiety-disorder trial. Valenta-funded report with sponsor-affiliated authors; 28-day efficacy and safety require longer independent follow-up.
V.M. Bekhterev Review of Psychiatry and Medical Psychology. 58(4-2):78–99 · Original journal publication
Randomized study in people · 2023
168-person dose-finding trial: the 6 mg group outperformed placebo
- Primary CGI-I response · 6 mg/day
- 57.1% versus 28.6% placeboDay 29p=0.0148
- Primary CGI-I response · 3 / 9 mg/day
- 39.5% / 43.9%Neither significantly exceeded placebo
At day 29, marked or substantial clinician-rated improvement occurred in 57.1% at 6 mg/day versus 28.6% with placebo (p=0.0148). The 3 mg and 9 mg groups did not significantly outperform placebo on that primary endpoint.
Study notes · methods, sources and limitations
Participants or model 168 randomized: 3 mg/day n=43, 6 mg/day n=42, 9 mg/day n=41, placebo n=42; 165 completed per protocol.
- Analysis populations
- 168 intention-to-treat; 165 per protocol
Important limitations
- Randomized double-blind study in neurasthenia/adjustment disorders; generalized anxiety disorder was excluded. Sponsor-affiliated investigators; four-week findings do not establish long-term benefit.
Clinical Pharmacology and Therapy. 32(4):36–40 · Original journal publication
Randomized study in people · 2026
2026 active-comparator trial reported higher response than Afobazol
- Reported ≥50% HARS response
- 63.3% (62 patients) versus 49.0% (49 patients)Day 29p<0.043
- Arm-level patients with adverse events
- 16/100 versus 12/100Overall count in abstract is inconsistent; arm-level figures retained as printedp=0.4150
The open trial reported ≥50% HARS improvement in 63.3% (62 patients) with Ranquilon versus 49.0% (49 patients) with Afobazol at day 29 (p<0.043).
Study notes · methods, sources and limitations
Participants or model 200 randomized: Ranquilon 100; Afobazol 100.
Important limitations
- Active-comparator, open-label trial; this is not a blinded placebo comparison. The abstract does not reconcile 62 responders/63.3% with 100 randomized in that arm. Its combined adverse-event patient count is also internally inconsistent; do not silently reconstruct denominators.
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 126(7):51–62 · Original journal publication
About GB-115 & CCK analogues
Names in this research collection
GB-115 · Ranquilon · Rankvilon · Ранквилон · GB-101 · CCK-4 · Cholecystokinin
Identity / background source ↗
Research background
A synthetic CCK-4-related dipeptide derivative studied as Ranquilon in randomized human anxiety trials; related CCK-4 and stereochemical compounds are kept distinct.
From a panic-provoking peptide to an anxiety-drug candidate
CCK-4 can provoke panic symptoms in laboratory challenges. In one randomized, double-blind study of 36 healthy volunteers, panic occurred in 11%, 17% and 47% of challenges at increasing CCK-4 doses, and in none after placebo. Original challenge study →
GB-115 is a different molecule. Its developers used CCK-4 as a starting point for smaller peptide derivatives. In the 2007 rat experiments, derivatives containing L-tryptophan reduced anxiety-like behavior, while the D-tryptophan series increased it. GB-115 belongs to the L-series. Design and stereochemistry →
Which anxiety conditions were studied?
The early 31-person pilot enrolled people with generalized anxiety disorder. The larger phase II and III placebo trials instead enrolled adults with anxiety associated with neurasthenia or adjustment disorders. Those populations should retain their original diagnoses when interpreting the results.
The 2026 study compared Ranquilon with Afobazol openly. It adds active-comparator evidence, while the two earlier randomized, double-blind trials provide the inactive-placebo comparisons. Published receptor descriptions have changed over time; the design history alone does not establish receptor subtype selectivity.
Compare the placebo trials → · 2026 active-comparator report →
- Compound class
- Peptide research family
- Research collection
- Neuropeptide research · editorial grouping
- Institutions in linked studies
- See individual study records
- Source review
- Review dates and the material assessed are listed with each publication below.
Understanding the evidence
Human research
Randomized placebo trials (168 and 220 participants), an open active-comparator trial (200), and pilot reports
Study methods
Phase II and III explicitly double-blind; phase IV compares active treatments openly
Independent replication
Independent replication not established by the records collected here
Source access
Primary abstracts, selected full texts, patents and explicit retrieval targets
Safety evidence
Phase III adverse events: 28/110 active versus 16/110 placebo; short follow-up
Open a topic for the evidence assessment.
Patents and claimed inventions
These 2 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.
Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →
Findings by study
Experiment described in a patent · 2019
GB-115: activating anxiolytic application — RU2709013C1
The clinical narrative describes reduced anxiety with improved sleep, energy and concentration.
Illustrative course · Improvement began toward the end of week 1; somatic/autonomic anxiety symptoms largely reduced by week 3 · Single selected case, not a controlled response rate · 21 days
Study notes and original source
GB-115: activating anxiolytic application — RU2709013C1
Patent-defined substance or composition · Patent publication
Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Григорий Георгиевич Незнамов, Сергей Борисович Середенин, Ольга Анатольевна Дорофеева, Марианна Вячеславовна Метлина · RU2709013C1 · patent family RU2709013C1
The clinical narrative describes reduced anxiety with improved sleep, energy and concentration.
Results and tables
Reported patent results
Findings described in words
The clinical narrative describes reduced anxiety with improved sleep, energy and concentration.
GB-115 patent clinical anxiety observations and an illustrated 21-day case; full arm sizes and outcome-table values were not extracted.
Population or model GB-115 patent clinical anxiety observations and an illustrated 21-day case; full arm sizes and outcome-table values were not extracted.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Illustrative course | Improvement began toward the end of week 1; somatic/autonomic anxiety symptoms largely reduced by week 3 | Single selected case, not a controlled response rate · 21 days |
| Clinical scale narrative | Reduced mental and autonomic anxiety symptoms reported | The source cites before/after significance; exact values and denominators not entered |
| Reported tolerability | No listed sedative/muscle-relaxant or excessive-stimulation effects reported | Limited patent observation; not a comprehensive safety comparison |
Selected cases and incompletely extracted group data do not independently confirm modern trial efficacy. Related clinical publications may describe the same development program.
Source for these results ↗ · Reviewed 2026-11-06
- Population / setting
- GB-115 patent clinical anxiety observations and an illustrated 21-day case; full arm sizes and outcome-table values were not extracted.
- Source reviewed
- Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
- The granted use is not independent confirmation of all clinical anxiety or cognition claims.
- Selected cases and incompletely extracted group data do not independently confirm modern trial efficacy. Related clinical publications may describe the same development program.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Reviewed 2026-11-06.
Experiment described in a patent · 2016
GB-115: solid dosage form — RU2602742C2
The solid formulation produced higher measured exposure and a longer circulating profile in the reported animal comparison.
Relative bioavailability · 192% relative to the reference substance · A formulation-specific rat ratio; not absolute oral bioavailability or a human value
Study notes and original source
GB-115: solid dosage form — RU2602742C2
Patent-defined substance or composition · Patent publication
Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Сергей Борисович Середенин, Татьяна Александровна Гудашева, Борис Михайлович Пятин, Нина Ивановна Авдюнина, Константин Викторович Алексеев, Любовь Николаевна Грушевская, Лариса Геннадьевна Колик, Владимир Павлович Жердев, Надежда Михайловна Зайцева, Евгения Викторовна Блынская, Ксения Геннадьевна Турчинская, Наталья Викторовна Тихонова, Людмила Михайловна Гаевая, Марк Александрович Константинопольский, Светлана Семеновна Бойко · RU2602742C2 · patent family RU2602742C2
The solid formulation produced higher measured exposure and a longer circulating profile in the reported animal comparison.
Results and tables
Reported patent results
Reported findings
The solid formulation produced higher measured exposure and a longer circulating profile in the reported animal comparison.
GB-115 solid-form versus unformulated-substance pharmacokinetics in rats, with behavioral comparisons.
Population or model GB-115 solid-form versus unformulated-substance pharmacokinetics in rats, with behavioral comparisons.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Relative bioavailability | 192% relative to the reference substance | A formulation-specific rat ratio; not absolute oral bioavailability or a human value |
| Elimination and residence | Half-life 44.75 minutes; mean residence time 68.32 minutes; elimination constant 0.0155/min | Parameters reported for the formulation · Rat pharmacokinetics |
| Time profile | A second maximum described around 40–60 minutes; detectable through 90 minutes | The proposed recirculation explanation is not directly proven |
Rat exposure and behavior do not establish a superior human anxiolytic effect. The pharmacokinetic values cannot be transferred to a different product.
Source for these results ↗ · Reviewed 2026-11-06
- Population / setting
- GB-115 solid-form versus unformulated-substance pharmacokinetics in rats, with behavioral comparisons.
- Source reviewed
- Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
- Formulation protection is distinct from proof of clinical benefit or from the base-compound discovery claim.
- Rat exposure and behavior do not establish a superior human anxiolytic effect. The pharmacokinetic values cannot be transferred to a different product.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Reviewed 2026-11-06.
Randomized study in people · 2023
Ranquilon dose-finding in anxiety associated with neurasthenia and adjustment disorders: phase II trial
At day 29, marked or substantial clinician-rated improvement occurred in 57.1% at 6 mg/day versus 28.6% with placebo (p=0.0148). The 3 mg and 9 mg groups did not significantly outperform placebo on that primary endpoint.
Study notes and original source
Ranquilon dose-finding in anxiety associated with neurasthenia and adjustment disorders: phase II trial
GB-115 / Ranquilon (L-tryptophan dipeptide derivative) · Original journal publication
O. V. Goncharov, D. Ch. Mavani, A. A. Ledovskikh, L. A. Tsukurova, M. M. Gavrik, I. V. Balaban, A. A. Globenko, A. V. Kapashin, M. A. Pasko · Clinical Pharmacology and Therapy. 32(4):36–40
At day 29, marked or substantial clinician-rated improvement occurred in 57.1% at 6 mg/day versus 28.6% with placebo (p=0.0148). The 3 mg and 9 mg groups did not significantly outperform placebo on that primary endpoint.
Results and tables
Reported findings and study design
At day 29, marked or substantial clinician-rated improvement occurred in 57.1% at 6 mg/day versus 28.6% with placebo (p=0.0148). The 3 mg and 9 mg groups did not significantly outperform placebo on that primary endpoint.
Population or model 168 randomized: 3 mg/day n=43, 6 mg/day n=42, 9 mg/day n=41, placebo n=42; 165 completed per protocol.
Dose, route and schedule
Oral 3, 6 or 9 mg/day, split three times daily, or matching placebo for 28 days. Study methods, not a recommended personal regimen.
Protocol source ↗ · Publisher full-text HTML methods and results checked.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Primary CGI-I response · 6 mg/day | 57.1% versus 28.6% placebo | Day 29 · p=0.0148 |
| Primary CGI-I response · 3 / 9 mg/day | 39.5% / 43.9% | Neither significantly exceeded placebo |
| Analysis populations | 168 intention-to-treat; 165 per protocol |
Phase II primary CGI-I response
| Group | Randomized | ITT response | PP response |
|---|---|---|---|
| 3 mg/day | 43 | 39.5% | 40.5% |
| 6 mg/day | 42 | 57.1% | 58.5% |
| 9 mg/day | 41 | 43.9% | 45.0% |
| Placebo | 42 | 28.6% | 28.6% |
Response: CGI-I 1 or 2 at day 29. ITT n=168; PP n=165. Only the 6 mg/day comparison reached significance versus placebo.
Randomized double-blind study in neurasthenia/adjustment disorders; generalized anxiety disorder was excluded. Sponsor-affiliated investigators; four-week findings do not establish long-term benefit.
Source for these results ↗ · Reviewed 2026-11-01
- Population / setting
- 168 randomized: 3 mg/day n=43, 6 mg/day n=42, 9 mg/day n=41, placebo n=42; 165 completed per protocol.
- Source reviewed
- Publisher full-text HTML methods and results checked.
Study limitations
- Randomized double-blind study in neurasthenia/adjustment disorders; generalized anxiety disorder was excluded.
- Sponsor-affiliated investigators; four-week findings do not establish long-term benefit.
Reviewed 2026-11-01.
Randomized study in people · 2024
Ranquilon in anxiety associated with neurasthenia and adjustment disorder: randomized double-blind placebo-controlled phase III trial
At day 29, 77/110 (70.0%) Ranquilon recipients achieved at least a 50% HARS anxiety-score reduction versus 27/110 (24.5%) on placebo (p<0.0001). The reported response-rate difference was 45.5 percentage points.
Study notes and original source
Ranquilon in anxiety associated with neurasthenia and adjustment disorder: randomized double-blind placebo-controlled phase III trial
GB-115 / Ranquilon (L-tryptophan dipeptide derivative) · Original journal publication
T. A. Karavayeva, E. M. Krupitsky, A. N. Barinov, L. G. Kolik, K. A. Ishchenko, K. K. Khacheva · V.M. Bekhterev Review of Psychiatry and Medical Psychology. 58(4-2):78–99
At day 29, 77/110 (70.0%) Ranquilon recipients achieved at least a 50% HARS anxiety-score reduction versus 27/110 (24.5%) on placebo (p<0.0001). The reported response-rate difference was 45.5 percentage points.
Results and tables
Reported findings and study design
At day 29, 77/110 (70.0%) Ranquilon recipients achieved at least a 50% HARS anxiety-score reduction versus 27/110 (24.5%) on placebo (p<0.0001). The reported response-rate difference was 45.5 percentage points.
Population or model 220 adults, 110 Ranquilon and 110 placebo; 28 days of treatment.
Dose, route and schedule
Ranquilon 6 mg/day orally (2 mg three times daily) or matching placebo for 28 days. Study methods, not a recommended personal regimen.
Protocol source ↗ · Original 22-page journal PDF: methods, bilingual summary and selected numerical results checked.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Primary ≥50% HARS response | 77/110 (70.0%) versus 27/110 (24.5%) | Day 29 ± 1 · p<0.0001 |
| Response-rate difference | 45.5 percentage points | Absolute difference, not a 45.5% relative reduction |
| HARS decrease · day 29 | 11.90 ± 4.88 versus 5.43 ± 5.03 points | p<0.0001 |
| Patients with adverse events | 28/110 (25.5%) versus 16/110 (14.6%) | p=0.063 |
| Adverse-event counts | 43 active-arm events; 21 placebo-arm events | No serious events or adverse-event discontinuations reported |
Phase III reported comparisons
| Endpoint | Ranquilon (n=110) | Placebo (n=110) | Comparison |
|---|---|---|---|
| HARS response ≥50%, day 15 | 32 (29.1%) | 6 (5.5%) | p<0.0001 |
| HARS response ≥50%, day 29 | 77 (70.0%) | 27 (24.5%) | p<0.0001 |
| HARS decrease, day 15 | 7.47 ± 5.11 | 2.91 ± 3.04 | p<0.0001 |
| HARS decrease, day 29 | 11.90 ± 4.88 | 5.43 ± 5.03 | p<0.0001 |
| Patients with adverse events | 28 (25.5%) | 16 (14.6%) | p=0.063 |
HARS decreases are mean ± SD points. Response and adverse-event denominators are patients; event totals are separate.
Neurasthenia and adjustment disorders; do not relabel this as a generalized-anxiety-disorder trial. Valenta-funded report with sponsor-affiliated authors; 28-day efficacy and safety require longer independent follow-up.
Source for these results ↗ · Reviewed 2026-11-01
- Population / setting
- 220 adults, 110 Ranquilon and 110 placebo; 28 days of treatment.
- Source reviewed
- Original 22-page journal PDF: methods, bilingual summary and selected numerical results checked.
Study limitations
- Neurasthenia and adjustment disorders; do not relabel this as a generalized-anxiety-disorder trial.
- Valenta-funded report with sponsor-affiliated authors; 28-day efficacy and safety require longer independent follow-up.
Reviewed 2026-11-01.
Randomized study in people · 2026
Ranquilon versus Afobazol for anxiety in neurasthenia and adjustment disorders: open randomized phase IV comparison
The open trial reported ≥50% HARS improvement in 63.3% (62 patients) with Ranquilon versus 49.0% (49 patients) with Afobazol at day 29 (p<0.043).
Study notes and original source
Ranquilon versus Afobazol for anxiety in neurasthenia and adjustment disorders: open randomized phase IV comparison
GB-115 / Ranquilon (L-tryptophan dipeptide derivative) · Original journal publication
T. A. Karavayeva, A. N. Barinov, I. V. Egorov, E. Yu. Ebzeeva, K. A. Ishchenko · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 126(7):51–62
The open trial reported ≥50% HARS improvement in 63.3% (62 patients) with Ranquilon versus 49.0% (49 patients) with Afobazol at day 29 (p<0.043).
Results and tables
Reported findings and study design
The open trial reported ≥50% HARS improvement in 63.3% (62 patients) with Ranquilon versus 49.0% (49 patients) with Afobazol at day 29 (p<0.043).
Population or model 200 randomized: Ranquilon 100; Afobazol 100.
Dose, route and schedule
Ranquilon 6 mg/day or Afobazol (fabomotizole) 30 mg/day orally for 28 days. Study methods, not a recommended personal regimen.
Protocol source ↗ · Publisher abstract and references checked; full 2026 article not accessed.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Reported ≥50% HARS response | 63.3% (62 patients) versus 49.0% (49 patients) | Day 29 · p<0.043 |
| Arm-level patients with adverse events | 16/100 versus 12/100 | Overall count in abstract is inconsistent; arm-level figures retained as printed · p=0.4150 |
Active-comparator, open-label trial; this is not a blinded placebo comparison. The abstract does not reconcile 62 responders/63.3% with 100 randomized in that arm. Its combined adverse-event patient count is also internally inconsistent; do not silently reconstruct denominators.
Source for these results ↗ · Reviewed 2026-11-01
- Population / setting
- 200 randomized: Ranquilon 100; Afobazol 100.
- Source reviewed
- Publisher abstract and references checked; full 2026 article not accessed.
Study limitations
- Active-comparator, open-label trial; this is not a blinded placebo comparison.
- The abstract does not reconcile 62 responders/63.3% with 100 randomized in that arm. Its combined adverse-event patient count is also internally inconsistent; do not silently reconstruct denominators.
Reviewed 2026-11-01.
Animal research · 2007
CCK-4 dipeptide analogue design: opposite behavioral effects of L- and D-tryptophan derivatives
L-tryptophan derivatives showed anxiety-reducing effects, while D-tryptophan derivatives produced anxiety-like behavior. GB-115 was selected from the L-tryptophan series, with reported rat activity at 0.05–0.2 mg/kg.
Study notes and original source
CCK-4 dipeptide analogue design: opposite behavioral effects of L- and D-tryptophan derivatives
GB-115 and related L-/D-tryptophan analogues · Original journal publication
Gudasheva TA, Kir'ianova EP, Kolik LG, Konstantinopol'skiĭ MA, Seredenin SB · Bioorg Khim 33:413-420
L-tryptophan derivatives showed anxiety-reducing effects, while D-tryptophan derivatives produced anxiety-like behavior. GB-115 was selected from the L-tryptophan series, with reported rat activity at 0.05–0.2 mg/kg.
Results and tables
Reported findings and study design
L-tryptophan derivatives showed anxiety-reducing effects, while D-tryptophan derivatives produced anxiety-like behavior. GB-115 was selected from the L-tryptophan series, with reported rat activity at 0.05–0.2 mg/kg.
Population or model Medicinal-chemistry series and rat anxiety models.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Rat anxiety-model activity | 0.05–0.2 mg/kg GB-115; opposite effects in L/D series |
Stereochemical findings are from animal experiments; D-GB-115 and GB-115 are distinct compounds.
Source for these results ↗ · Reviewed 2026-11-01
- Population / setting
- Medicinal-chemistry series and rat anxiety models.
- Source reviewed
- Primary indexed English abstract checked.
Study limitations
- Stereochemical findings are from animal experiments; D-GB-115 and GB-115 are distinct compounds.
Reviewed 2026-11-01.
Randomized study in people · 1991
Dose-ranging CCK-4 panic-challenge study in healthy volunteers
Panic attacks occurred after CCK-4 in 11%, 17% and 47% of challenges at 9, 25 and 50 micrograms, respectively; none occurred with placebo.
CCK-4 panic incidence · 11% / 17% / 47% across increasing doses; 0 with placebo
Study notes and original source
Dose-ranging CCK-4 panic-challenge study in healthy volunteers
CCK-4 (tetragastrin); no GB-115 administered · Original journal publication
Bradwejn J, Koszycki D, Bourin M · J Psychiatry Neurosci 16:91-95
Panic attacks occurred after CCK-4 in 11%, 17% and 47% of challenges at 9, 25 and 50 micrograms, respectively; none occurred with placebo.
Results and tables
Reported findings and study design
Panic attacks occurred after CCK-4 in 11%, 17% and 47% of challenges at 9, 25 and 50 micrograms, respectively; none occurred with placebo.
Population or model 36 healthy volunteers in randomized double-blind challenge conditions.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| CCK-4 panic incidence | 11% / 17% / 47% across increasing doses; 0 with placebo |
CCK-4 challenge experiment, not GB-115 administration or an anxiety-treatment trial.
Source for these results ↗ · Reviewed 2026-11-01
- Population / setting
- 36 healthy volunteers in randomized double-blind challenge conditions.
- Source reviewed
- Primary indexed English abstract checked.
Study limitations
- CCK-4 challenge experiment, not GB-115 administration or an anxiety-treatment trial.
Reviewed 2026-11-01.
Observational study · 2019
[Results of a clinical study of a new anxiolytic, a blocker of central cholecystokinin receptors].
A 31-person, 21-day uncontrolled GB-115 pilot reported improvements in anxiety, attention and sleep; it does not quantify an advantage over placebo or standard drugs.
Study notes and original source
[Results of a clinical study of a new anxiolytic, a blocker of central cholecystokinin receptors].
Neznamov GG, Dorofeeva OA, Metlina MV, Syunyakov TS, Minaev SV, Ivashkina NY, Martyanov VA, Seredenin SB · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
A 31-person, 21-day uncontrolled GB-115 pilot reported improvements in anxiety, attention and sleep; it does not quantify an advantage over placebo or standard drugs.
Results and tables
Reported findings and study design
A 31-person, 21-day uncontrolled GB-115 pilot reported improvements in anxiety, attention and sleep; it does not quantify an advantage over placebo or standard drugs.
31 adults with generalized anxiety disorder, aged 22–53: 22 women, 9 men.
Dose, route and schedule
GB-115 was studied as 1 mg tablets during 21 days of treatment. The authors identified 6 mg/day as the effective dose in this report; the abstract does not give a divided-dose schedule.
Protocol source ↗ · Indexed publication abstract
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Anxiety and cognitive measures | Reported favorable changes; no numerical scale deltas in indexed abstract | |
| Participants | 31 (22 women; 9 men) | |
| Studied dose and duration | Effective dose described as 6 mg/day; 21 days |
This pilot is distinct from the larger phase II/III reports, and possible overlap with later 25-person conference analyses remains flagged.
Source for these results ↗ · Reviewed 2026-11-01
- Population / setting
- 31 adults with generalized anxiety disorder
- Source reviewed
- Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Study limitations
- Uncontrolled pilot evidence; expectancy and repeated-testing effects remain possible.
- Later 25-patient conference analyses may overlap and are not counted as independent replication.
Reviewed 2026-11-01.
Animal research · 2013
Anxiolytic activity of dipeptide GB-115 after oral administration.
Oral GB-115 changed anxiety-related behavior in rodents, with effects depending on strain and stress-response phenotype.
Study notes and original source
Anxiolytic activity of dipeptide GB-115 after oral administration.
Kolik LG, Konstantinopolsky MA, Ryibina IV, Povarnina PY, Gudasheva TA, Seredenin SB · Bulletin of experimental biology and medicine
Oral GB-115 changed anxiety-related behavior in rodents, with effects depending on strain and stress-response phenotype.
- Population / setting
- Rodents; open-field and elevated-plus-maze experiments
- Source reviewed
- Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Study limitations
- Preclinical findings do not establish human benefit or safety.
- Abstract only. Full methods and independent replication remain unconfirmed.
Reviewed 2026-10-05.
Animal research · 2012
Role of the cholecystokinin system in anxiolytic activity of dipeptide GB-115.
GB-115 countered some CCK-4-induced behavioral responses but not yohimbine-induced anxiety in C57Bl/6 mice, indicating model-dependent effects rather than universal anxiolysis.
Study notes and original source
Role of the cholecystokinin system in anxiolytic activity of dipeptide GB-115.
Kolik LG, Gudasheva TA, Seredenin SB · Bulletin of experimental biology and medicine
GB-115 countered some CCK-4-induced behavioral responses but not yohimbine-induced anxiety in C57Bl/6 mice, indicating model-dependent effects rather than universal anxiolysis.
- Population / setting
- Rats and BALB/c and C57Bl/6 mice
- Source reviewed
- Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Study limitations
- Preclinical findings do not establish human benefit or safety.
- Abstract only. Full methods and independent replication remain unconfirmed.
Reviewed 2026-10-05.
Review of earlier studies · 2018
Novel Technologies for Dipeptide Drugs Design and their Implantation.
The developers distinguish drug-inspired peptide design (Noopept and Dilept) from mimicking peptide/protein turns (GB-115 and GK-2). This is a historical design framework, not evidence of a shared clinical effect.
Study notes and original source
Novel Technologies for Dipeptide Drugs Design and their Implantation.
Gudasheva TA, Ostrovskaya RU, Seredenin SB · Current pharmaceutical design
The developers distinguish drug-inspired peptide design (Noopept and Dilept) from mimicking peptide/protein turns (GB-115 and GK-2). This is a historical design framework, not evidence of a shared clinical effect.
- Population / setting
- Developer account of medicinal-chemistry programs
- Source reviewed
- Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Study limitations
- Developer review; claims require appraisal of each original study.
- A shared design method does not establish equivalent biology or clinical benefit.
Reviewed 2026-10-05.
Observational study · 2022
Clinical effects of GB-115 in patients with Generalized Anxiety Disorder
A conference post-hoc analysis of 25 patients reported lower anxiety and fatigue scores over 21 days. Its relationship to the earlier pilot must be resolved before treating it as independent evidence.
Study notes and original source
Clinical effects of GB-115 in patients with Generalized Anxiety Disorder
· Conference abstract
· European Psychiatry. 65(Suppl 1):S388
A conference post-hoc analysis of 25 patients reported lower anxiety and fatigue scores over 21 days. Its relationship to the earlier pilot must be resolved before treating it as independent evidence.
- Population / setting
- 25 patients; uncontrolled conference report
- Source reviewed
- Selected original-source text checked; full methodological review pending.
Study limitations
- Conference abstract, not a full clinical report.
- No placebo comparison; possible overlap with the 31-patient pilot.
Reviewed 2026-10-05.
Related compound research
Follow shared publications or research classes. These links do not establish equivalent effects between compounds.
Research collection curated by @PepMariner · editorial standards. Send a source correction ↗
Browse bibliography & PDFs ↗